UCB S.A. won US Food and Drug Administration approval for two key products needed to help the company return to growth – Bimzelx (bimekizumab-bkzx) for adults with moderate-to-severe plaque psoriasis on 18 October and Zilbrysq (zilucoplan) for adults with generalized myasthenia gravis (gMG) on 17 October. Bimzelx will launch in a month and Zilbrysq will be available around the end of 2023, but both are expected to be big contributors to UCB’s goal of achieving €6bn in annual revenue by 2025.
The Belgian pharma firm ended 2022 with €5.52bn in revenue, down 4% from 2021, and UCB expects its 2023 revenue to drop to €5.15bn-€5.35bn, largely based on the loss of patent exclusivity in the US and EU last year for one of its biggest sellers, the anti-seizure medication Vimpat (lacosamide)
